News & Videos - SUMMIT THERAPEUTICS ORD 1P

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”) AIM Delisting Reminder Oxford, UK, and Cambridge, MA, US, 11 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, issues a reminder that, as previously announced and pursuant to AIM Rule 41, the Company’s ordinary shares of one penny nominal value (“Ordinary Shares”) will cease to be admitted to trading on AIM at 7.00 am on 24 February 2020. Accordingly, the final day of...

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”) Notification of Transaction of Persons Discharging Managerial Responsibilities Oxford, UK, and Cambridge, MA, US, 10 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 7 February 2020, Dr Elaine Stracker, a Non-Executive Director of the Company, was assigned for no consideration warrants to acquire a total of 2,099,207...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Milestone Based on Achievement of Patient Enrolment Target in Phase 3 Clinical Trials of Ridinilazole Oxford, UK, and Cambridge, MA, US, 6 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA (‘Eurofarma’). The...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference Oxford, UK, and Cambridge, MA, US, 4 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 2020 BIO CEO & Investor Conference on 10 February 2020 at 2:15pm EST in New York City. A live webcast of the presentation will be available in the Investors section of the Company's...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Exercise of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 27 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that following the exercise of restricted stock units by former directors, the Company has issued 269,230 new ordinary shares of one penny each (the “New Ordinary Shares”). Application has been made for the admission to trading on AIM...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Management Update Oxford, UK, and Cambridge, MA, US, 24 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that Dr David Roblin has resigned as Chief Operating Officer, Chief Medical Officer and President of R&D, effective 31 January 2020. “David has been instrumental in establishing our leadership position in new mechanism antibiotic development and launching our Phase 3 clinical...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work Total Committed BARDA Funding Increased to $62.4 Million Total Award Increased to up to $72.5 Million Oxford, UK, and Cambridge, MA, US, 23 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that the Biomedical Advanced Research and Development...

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Summit Therapeutics PLC Sedol BN40HZ0 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate...

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Summit Therapeutics PLC Sedol BN40HZ0 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate...

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”) Notification of Transactions of Persons Discharging Managerial Responsibilities Oxford, UK, and Cambridge, MA, US, 15 January 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 14 January 2020, Mr Robert W. Duggan, a Non-Executive Director of the Company, sold a total of 33,321,870 ordinary shares and transferred a total of 4,998,279...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection Oxford, UK, and Cambridge, MA, US, 7 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today launched www.ricodify.com , an online resource for patients with C. difficile infection (‘CDI’) and their caregivers. The site provides information about CDI, the role of the microbiome in CDI and Summit’s ongoing Phase 3 clinical trials...

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Summit Therapeutics PLC Sedol BN40HZ0 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) An acquisition or disposal of voting rights X An acquisition...

TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Summit Therapeutics PLC Sedol BN40HZ0 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate...

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”) Completion of $50 million Subscription and Placing and Directorate Changes Oxford, UK, and Cambridge, MA, US, 24 December 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that the subscription and placing of new ordinary shares and warrants (the “ Fundraising ”) to raise approximately $50 million, which was approved by shareholders at the Company’s general meeting held...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Award of Share Options Oxford, UK, and Cambridge, MA, US, 24 December 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces a grant of options over new ordinary shares of one penny nominal value (‘Ordinary Shares’) on 23 December 2019 to Mr Manmeet Soni, Dr Elaine Stracker and Dr Ventzislav Stefanov. The Company has also made a grant of share options to certain Company...

Summit Therapeutics plc (‘Summit’ or the ’Company’) Exercise of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 24 December 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the exercise by Leopoldo Zambeletti, a Non-Executive Director of Summit, of restricted stock units (‘RSUs’) that entitled the holder to subscribe for an ordinary share of one penny nominal value at a subscription price of one penny per ordinary share. The RSUs were granted under the...

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”) Result of General Meeting, Admission of Fundraising Shares and Directorate Changes Oxford, UK, and Cambridge, MA, US, 23 December 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that at a general meeting of the Company held today in London, in connection with the proposed subscription and placing of new ordinary shares to raise approximately $50 million announced by the...

Summit Therapeutics plc (“Summit Therapeutics” or the “Company”) Timetable update for the proposed Subscription and Placing Oxford, UK, and Cambridge, MA, US, 19 December 2019 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that, further to the announcement made on 6 December 2019 regarding a fundraising of approximately $50 million through a subscription and placing of new ordinary shares and warrants to existing investors, the expected...

Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019 Oxford, UK, and Cambridge, MA, US, 17 December 2019 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today reports its financial results and provides an update on its operational progress for the third quarter and nine months ended 31 October 2019. “Our enthusiasm for ridinilazole...

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2019 on 17 December 2019 Oxford, UK, and Cambridge, MA, US, 16 December 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism antibiotic innovation, will announce its financial results for the third quarter and nine months ended 31 October 2019 on 17 December 2019. About Summit Therapeutics Summit...